Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder?

Email this article to a friend

Oscar G Bukstein^*, L Eugene Arnold, Jeanne M Landgraf and Paul Hodgkins

Child and Adolescent Psychiatry and Mental Health 2009, 3:39 doi:10.1186/1753-2000-3-39